Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an announcement.
Shanghai Fosun Pharmaceutical has announced the approval of Tenapanor Hydrochloride Tablets for controlling serum phosphorus levels in dialysis patients with chronic kidney disease. This approval by the National Medical Products Administration marks a significant step for Fosun Pharma, enhancing its product portfolio and potentially improving its market positioning in the treatment of CKD.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating in the pharmaceutical industry. It focuses on the development, manufacturing, and distribution of pharmaceutical products, with a market emphasis on innovative drugs and healthcare services.
YTD Price Performance: 14.20%
Average Trading Volume: 5,317
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $8.57B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.